Rise Advisors’s Nektar Therapeutics NKTR Stock Holding History

Rise Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-69	Closed	-$3.93K	–	979
2025 Q3	$3.93K	Buy	69 +20	+41%	+$662	﹤0.01%	1158
2025 Q2	$1.27K	Buy	+49	New	+$550	﹤0.01%	1251

Other funds holding NKTR

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rise Advisors's NKTR Position: Q4 2025 in Review

Rise Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2025, closing a stake of 69 shares — an estimated $3.93K sold.

Rise Advisors first reported a position in NKTR in Q2 2025 and held it in 2 quarters. The position peaked at $3.93K in Q3 2025. 180 funds tracked by Wall St. Rank hold NKTR as of Q4 2025.

Rise Advisors reported no remaining Nektar Therapeutics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 69 Nektar Therapeutics shares in Q4 2025, an estimated $3.93K.
Rise Advisors first reported a position in Nektar Therapeutics in Q2 2025 and held it in 2 quarters.
Rise Advisors's Nektar Therapeutics position peaked at $3.93K in Q3 2025.
180 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.